Please login to the form below

Not currently logged in
Email:
Password:

tramiprosate

This page shows the latest tramiprosate news and features for those working in and with pharma, biotech and healthcare.

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Earlier this week another drug in that category, Alzheon’s tramiprosate, also reported some encouraging data in a mid-stage trial, although that involved a subgroup of patients with a genetic

Latest news

  • Alzheon says data backs potential of Alzheimer's candidate Alzheon says data backs potential of Alzheimer's candidate

    The cognitive effect increased significantly with time, suggesting a potential disease-modifying effect of tramiprosate," they conclude. ... Tramiprosate is thought to work by inhibiting the aggregation of beta amyloid monomers into toxic oligomers.

  • Signalling change

    Another once-promising anti-amyloid drug, tramiprosate, was also abandoned by Bellus Health due to inconclusive phase III study findings.

  • Halted in its tracks

    Tramiprosate is a B-amyloid inhibitor that is currently in phase III development with Neurochem. ... Data presented at ICAD 2006 showed tramiprosate halts B-amyloid-induced neuronal cell death in rats.

  • Dealing with dementia

    A promising late-stage candidate is Neurochem's Alzhemed (tramiprosate). This drug works by mimicking and binding to glycosaminoglycan (GAG), which promotes the formation of the amyloid-beta plaques.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics